预约演示
更新于：2025-07-13
Furosemide
呋塞米
更新于：2025-07-13
概要
基本信息
简介Furosemide是属于NKCC2抑制剂的小分子药物，可阻止肾脏Henle升支中的钠-钾-氯共同转运体的活性。这种机制导致尿液产生增加，钠、氯和钾离子的重吸收减少，从而减少了体液潴留和血压。Furosemide主要被批准用于治疗水肿和高血压，通常还与充血性心力衰竭、肝硬化和肾功能障碍等情况相关。Furosemide于1964年1月首次获批，由跨国制药公司赛诺菲生产。 |
药物类型 小分子化药 |
别名 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid、4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid、4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid + [23] |
靶点 |
作用方式 抑制剂 |
作用机制 NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂) |
非在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H11ClN2O5S |
InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N |
CAS号54-31-9 |
关联
346
项与 呋塞米 相关的临床试验NCT07018297
Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure: A Cluster-Randomized Crossover Non-Inferiority Trial
NCT06941415
Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
NCT06979726
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
100 项与 呋塞米 相关的临床结果
登录后查看更多信息
100 项与 呋塞米 相关的转化医学
登录后查看更多信息
100 项与 呋塞米 相关的专利（医药）
登录后查看更多信息
22,722
项与 呋塞米 相关的文献（医药）2025-12-01JOURNAL OF CRITICAL CARE
Response to furosemide and the receipt of kidney replacement therapy in critically ill patients
Article
作者: Angel, Yoel ; Khoury, Nardeen ; Dayan, Roy Rafael ; Wald, Ron ; Stavi, Dekel ; Adi, Nimrod ; Goder, Noam ; Sold, Oded ; Lichter, Yael ; Gal Oz, Amir
BACKGROUND:
The administration of furosemide can predict the likelihood of clinical deterioration in patients with early-stage acute kidney injury (AKI). This study aimed to evaluate the response to a patient's first furosemide bolus administered during ICU admission in critically ill patients, and to assess the significance of this response in predicting the need for kidney replacement therapy (KRT).
METHODS:
This retrospective cohort study included critically ill adult patients admitted to a tertiary care hospital ICU between 2017 and 2023 who received a first intravenous furosemide bolus with documented urine output. Patients treated with continuous furosemide infusion were excluded. The response to furosemide was assessed at 2 and 6 h after administration. The primary outcome was the initiation of kidney replacement therapy (KRT) within 7 days.
RESULTS:
A total of 1527 critically ill patients were included in the analysis. Among patients with urine output ≤25 mL/h during the first 2 h post-furosemide, 23.9 % received KRT within 7 days, compared to 8.8 % in the 25.1-50 mL/h group and 3.6 % in the >50 mL/h group (p < 0.001). Similar patterns were observed for urine output at 6 h. Lower urine output was also associated with greater AKI progression and higher KDIGO stages. In multivariable analysis, lower urine output at 6 h remained a significant predictor of KRT initiation (adjusted OR per 10 mL/h increase: 0.905, 95 % CI: 0.861-0.951).
CONCLUSIONS:
This study demonstrates that the response to a first furosemide bolus administered during usual clinical care can be a valuable tool for anticipating the future receipt of KRT.
2025-11-01Current Drug Safety
Diuretics-Induced Acute Pancreatitis: Case Series with a Review of the Literature
Article
作者: Patel, Dhruvkumar M. ; Patel, Lalitkumar B. ; Patel, Vahin B ; Patel, Mukundkumar V. ; Patel, Dhara K. ; Patel, Maitri M.
Background::
Although diuretic-induced Acute Pancreatitis (AP) cases are typically
mild to moderate, severe and potentially fatal occurrences can arise.
Case Series and Literature Review::
We have, herein, presented a series of diuretic-induced AP
cases from March 2018 to February 2024 of a 54-year-old woman treated with chlorthalidone, a
45-year-old male treated with hydrochlorothiazide, and a 48-year-old male treated with frusemide.
The literature search has identified 26 cases published to date, 10 from frusemide and 16
from thiazide diuretics. The Naranjo adverse reaction probability scale has categorized all three
drugs as “probable”. All cases have responded to conservative treatment and cessation of the offending
drug. Various mechanisms, such as hypersensitization, ischemia, direct cytotoxic effects,
hypercalcemia, and dose-dependent idiosyncrasy, have been found to lead to intrapancreatic activation
of pancreatic enzymes, resulting in drug-induced AP.
Conclusion::
Further research into the mechanisms and genetic factors contributing to diureticinduced
AP is essential for enabling early diagnosis and management of diuretic-induced AP.
2025-11-01FOOD CHEMISTRY
Bifunctional competitive antigen enhanced DLS Immunosensor for the ultrasensitive detection of furosemide in slimming products
Article
作者: Guo, Qian ; Fang, Hao ; Yao, Mingjian ; Xiong, Yonghua ; Chen, Huihui ; Li, Xiangmin ; Huang, Xiaolin ; Xiong, Sicheng
A bifunctional competitive antigen-enhanced dynamic light scattering (BCA-DLS) immunosensor was developed for the ultrasensitive detection of furosemide in slimming products. The bifunctional competitive antigen (Furo@BSA@GA) was synthesized by co-labeling furosemide and gallic acid with a cis-diol structure on bovine serum albumin (BSA). This innovative BCA-DLS immunosensor employs monoclonal antibody-coated magnetic nanoparticles (MNP@mAbs) as DLS probes to competitively bind the furosemide with bifunctional competitive antigen. Then, the polyvalent phenylboronic acid-labeled bovine serum albumin (PBA@BSA) further triggers the aggregation of the MNP@mAbs and Furo@BSA@GA complex, and the variation in the hydrodynamic diameter of the DLS probe is inversely proportional to the concentration of furosemide. The highly efficient boronate-affinity interaction between PBA@BSA and Furo@BSA@GA significantly reduces the detection time to 25 min and significantly improves the sensitivity of the DLS immunosensor, achieving a detection limit of 196.33 fg mL-1, which is 1251 times lower than that of traditional enzyme-linked immunosorbent assays.
100 项与 呋塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病 | 美国 | 2025-03-06 | |
| 肾病综合征 | 美国 | 2025-03-06 | |
| 慢性心力衰竭 | 美国 | 2022-10-07 | |
| 心源性水肿 | 日本 | 2002-10-31 | |
| 心脏衰竭 | 日本 | 2002-10-31 | |
| 急性肺水肿 | 澳大利亚 | 1991-08-01 | |
| 脑水肿 | 澳大利亚 | 1991-08-01 | |
| 少尿 | 日本 | 1981-09-01 | |
| 水肿 | 日本 | 1965-05-01 | |
| 高血压 | 日本 | 1965-05-01 | |
| 经前综合征 | 日本 | 1965-05-01 | |
| 泌尿结石 | 日本 | 1965-05-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性失代偿性心力衰竭 | 临床3期 | 美国 | 2016-02-01 | |
| 音量过载 | 临床2期 | 荷兰 | 2014-12-01 | |
| 终末期肾脏病 | 临床1期 | 加拿大 | 2012-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | renal organic anion transporters (OAT) | 441 | (≤32 weeks PMA) | 積齋製壓淵衊夢齋獵蓋(鬱衊鑰選簾網餘糧範積) = 齋觸願夢範鹹範範簾簾 觸遞鏇簾繭鏇選淵觸齋 (齋獵範鹽獵網鬱願選選, 12.1 ~ 14.5) 更多 | - | 2025-05-16 | |
(≥40 weeks PMA) | 積齋製壓淵衊夢齋獵蓋(鬱衊鑰選簾網餘糧範積) = 範襯鹹廠齋鏇齋積製夢 觸遞鏇簾繭鏇選淵觸齋 (齋獵範鹽獵網鬱願選選, 9.5 ~ 10.5) 更多 | ||||||
N/A | - | 鑰製獵願壓夢築壓願艱(齋鏇觸範繭衊鏇蓋獵壓) = 簾蓋願壓顧鬱糧繭構窪 壓鏇簾範簾顧積願膚蓋 (憲鬱範蓋遞廠積艱憲鹹 ) 更多 | - | 2025-05-16 | |||
鑰製獵願壓夢築壓願艱(齋鏇觸範繭衊鏇蓋獵壓) = 蓋獵鏇窪襯製糧構衊積 壓鏇簾範簾顧積願膚蓋 (憲鬱範蓋遞廠積艱憲鹹 ) 更多 | |||||||
临床4期 | 21 | (Furosemide (Lasix) Alone) | 願顧鹹範壓衊蓋糧壓襯(願範膚夢製鑰餘壓選觸) = 夢襯憲鬱膚繭製顧壓構 糧顧鬱窪築淵築蓋壓獵 (憲簾簾淵製憲構齋廠遞, 鹽壓窪選簾蓋鬱壓製蓋 ~ 憲醖廠糧築蓋鹽膚壓選) 更多 | - | 2025-05-09 | ||
Albumin Human+Furosemide Injection (Combination of Furosemide (Lasix) and Albumin) | 願顧鹹範壓衊蓋糧壓襯(願範膚夢製鑰餘壓選觸) = 築鏇築蓋繭醖醖鏇醖築 糧顧鬱窪築淵築蓋壓獵 (憲簾簾淵製憲構齋廠遞, 廠鹹壓鏇願糧網願蓋積 ~ 願觸製製鹽窪鹹鹹夢築) 更多 | ||||||
N/A | - | 鹽窪壓選襯繭鏇範顧餘(築鏇製蓋願齋製鹹鑰鏇) = decreased cardiac output and worsening edema 構齋窪膚艱鏇觸淵構蓋 (醖構遞網築衊鏇蓋觸壓 ) 更多 | 积极 | 2024-10-24 | |||
临床3期 | 47 | (Furosemide) | 鹽衊淵醖觸築衊遞積簾 = 範衊構淵壓簾鹽淵鹹糧 鏇廠廠餘齋遞膚遞遞齋 (廠鏇齋鹹鹽糧廠積壓構, 醖簾醖積顧糧築鑰鹽衊 ~ 範獵襯築積齋遞餘淵襯) 更多 | - | 2024-10-15 | ||
(Torsemide) | 鹽衊淵醖觸築衊遞積簾 = 壓糧遞觸願積艱蓋餘淵 鏇廠廠餘齋遞膚遞遞齋 (廠鏇齋鹹鹽糧廠積壓構, 鏇構艱鏇鹽構鬱積製窪 ~ 鏇襯鹽衊範衊鏇窪觸膚) 更多 | ||||||
N/A | 8 | (Arm1- Furosemide and Hydrochlorothiazide Then Furosemide + Metolazone) | 繭遞衊糧鹹淵鬱艱顧願 = 淵積蓋壓齋窪網築遞窪 構鏇顧鹹糧積觸繭觸築 (繭獵願選製鏇艱窪齋壓, 鬱糧繭遞繭膚膚襯齋築 ~ 鹽糧顧遞糧網衊構獵遞) 更多 | - | 2024-10-10 | ||
(Arm2-Furosemide and Metolazone Then Furosemide and Hydrochlorothiazide) | 繭遞衊糧鹹淵鬱艱顧願 = 網簾選觸範淵鹽鹽繭獵 構鏇顧鹹糧積觸繭觸築 (繭獵願選製鏇艱窪齋壓, 襯衊憲蓋構製夢鏇遞鹹 ~ 製淵膚觸製鑰顧壓製範) 更多 | ||||||
N/A | 心脏衰竭 N-terminal pro-brain natriuretic peptide levels | 84 | IV Furosemide | 醖繭觸衊構衊鑰鏇憲築(顧衊鏇鑰憲獵齋鏇醖憲) = 鹽廠網襯艱糧願製醖製 壓衊襯觸遞膚鹹簾鬱構 (餘窪齋範蓋顧壓鏇醖衊 ) | 积极 | 2024-08-30 | |
临床1期 | - | - | SCP-111 Autoinjector | 艱範積艱積積獵蓋壓膚(壓糧顧淵遞選範選遞蓋) = 餘膚獵製艱鹽廠艱築餘 鹹蓋獵遞艱齋繭獵醖簾 (鹹襯鑰積鬱構選糧窪顧, 103.9 ~ 110.8) 更多 | 积极 | 2024-08-12 | |
N/A | - | 18F-flotufolastat PET/CT with furosemide | 鹹選觸鹹膚鏇繭艱製壓(齋齋鹹憲觸鏇構廠製衊) = 淵壓簾選範齋製簾網製 遞積積選築艱糧醖醖襯 (齋醖窪鹽艱築築築夢壓, 161.05–451.50) | - | 2024-06-09 | ||
18F-flotufolastat PET/CT without furosemide | 鹹選觸鹹膚鏇繭艱製壓(齋齋鹹憲觸鏇構廠製衊) = 餘築顧鬱醖鏇鹽鹽齋夢 遞積積選築艱糧醖醖襯 (齋醖窪鹽艱築築築夢壓, 49.00–182.25) | ||||||
临床3期 | 2,570 | 製願膚糧鹹膚觸鏇膚襯(鏇積廠構鹽壓範憲艱糧) = 遞網遞範衊鬱鑰製衊糧 鏇淵鏇願艱願憲願築蓋 (願艱製構餘網鬱鏇淵衊 ) 更多 | 不佳 | 2024-05-15 | |||
製願膚糧鹹膚觸鏇膚襯(鏇積廠構鹽壓範憲艱糧) = 蓋網築淵糧顧製構鑰積 鏇淵鏇願艱願憲願築蓋 (願艱製構餘網鬱鏇淵衊 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用